阐明向ATP结合盒子子子家族G成员2 (ABCG2) 的相互作用化合物的结合特异性
Pawan Kumar1, Indu Kumari2,3, Rajendra Prasad2
1School of Computational and Integrative Sciences, Jawaharlal Nehru University, New Delhi, India.
Molecular diversity
|January 9, 2025
概括
分子对接和模拟揭示了基板和抑制剂如何与ABCG2 (乳腺癌抵抗蛋白) 结合. 多塞塔克塞尔,塔里基达尔和特扎卡夫托尔表现出高的结合亲缘关系,有助于理解耐药性.
科学领域:
- 生物化学和分子生物学
- 药理学和药物发现
- 结构生物学 结构生物学
背景情况:
- 结合ATP的磁带载体超级家族对于细胞排毒和药物排放至关重要.
- ABCG2 (ATP结合盒子子子家族G成员2),也被称为乳腺癌耐药性蛋白质,与癌症多药性耐药性有关.
- 了解ABCG2的基质和抑制剂结合对于开发有效的癌症疗法至关重要.
研究的目的:
- 阐明在ABCG2.2的跨膜域内基质和抑制剂结合的分子基础.
- 使用计算方法识别潜在的候选药物和对ABCG2具有高度亲和力的抑制剂.
- 为了深入了解ABCG2介导药物排放和基质特异性的分子决定因素.
主要方法:
- 利用分子对接算法和分子动力学 (MD) 模拟来定义基质和抑制剂结合.
- 在药品银行数据库中进行虚拟选,以识别潜在的ABCG2结合剂.
- 估计的结合亲和力使用MM-GBSA (分子力学与一般化出生表面积) 计算和模拟复合体在POPC脂质双层.
主要成果:
- 据对接发现,Docetaxel,Tariquidar和Tezacaftor是ABCG2的结合亲和度最高的药物 (≤12.00 kcal/mol).
- 在MM-GBSA的结果中,Tariquidar与ABCG2的结合在测试的抑制剂中最稳定.
- 多塞塔克塞尔,奥扎尼莫德,皮塔瓦斯塔丁和特扎卡夫托尔对ABCG2的药物结合部位表现出强烈的亲和力.
结论:
- 这项研究提供了宝贵的见解,了解了通过ABCG2.2控制基质/抑制剂识别的关键残留物.
- 确定了对ABCG2具有高度亲和力的特定化合物,为治疗开发提供了潜在的潜力.
- 这些发现揭示了影响基质特异性,运输动力学和ABCG2.2介导的药物外流的分子决定因素.
相关概念视频
ABC Transporters: Importer
2.7K
ATP-binding cassette or ABC transporters are a class of ATP-driven pumps that hydrolyze ATP to move solutes across the membrane. They can be grouped into importers and exporters. While exporters are present in all domains of life, importers exist only in bacteria and some plants.
In bacteria, based on the number of transmembrane helices and the chemical nature of their substrates, the ABC importers can be divided into three types:
In bacteria, based on the number of transmembrane helices and the chemical nature of their substrates, the ABC importers can be divided into three types:
2.7K
ABC Transporters: Exporter
4.1K
ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
4.1K
Allosteric Proteins-ATCase
5.7K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.7K
Targets for Drug Action: Overview
6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K


